Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis

  • A.S. Koldkjær SøllingEmail author
  • T. Harsløf
  • B. Langdahl
Original Article



Treatment with zoledronic acid 5 mg maintained bone turnover markers in the premenopausal range, increased lumbar spine bone mineral density, and maintained hip bone mineral density in women previously treated with odanacatib 50 mg weekly.


The development of odanacatib (ODN), a cathepsin K inhibitor, for treatment of osteoporosis was discontinued due to an increased risk of cardiovascular events. As the treatment is considered reversible, participants from the LOFT trial in Aarhus, Denmark, were offered treatment with zoledronic acid (ZOL).


Sixty-seven postmenopausal women were treated with ZOL 5 mg and followed for 12 months. Of these, 39 had received ODN for 7 years and 28 had received placebo for 5 years and ODN for 2 years. Bone turnover markers (BTM) were measured 3, 6, and 12 months after ZOL, and DXA of spine and hip were performed at time of ZOL treatment and after 12 months.


Within the entire study population, BMD at the lumbar spine increased by 2.8 ± 0.9% (mean ± SEM) (p < 0.01) from baseline to month 12. There was no significant change in BMD at the total hip (p = 0.17) or femoral neck (p = 0.39). There was no difference in the changes in BMD from baseline to 12 months between the two groups at any site (p ≥ 0.20 for all). CTX increased by 107 ± 9% (p < 0.001), PINP by 102 ± 16% (p < 0.001), osteocalcin by 32 ± 6% (p = 0.001) and BSAP by 79 ± 37% (p = 0.001) between 3 and 12 months after ZOL. At month 12, BTM were still within the premenopausal reference range. S-25-hydroxyvitamin D increased (p = 0.059), while PTH (p = 0.007) and eGFR (p = 0.014) decreased during the year following ZOL administration.


Treatment with ZOL 5 mg maintained BTMs in the premenopausal range and prevented bone loss in women previously treated with ODN.


Bone turnover markers Cathepsin K inhibitor Odanacatib Osteoporosis Zoledronic acid 


Compliance with ethical standards

Conflict of interest

Torben Harsløf received lecture fees from Amgen, Astra Zeneca, and Eli Lilly. Bente Langdahl is a consultant for MSD, Amgen, Eli Lilly, and UCB and has received lecture fees from MSD, Eli Lilly, and Amgen. Anne Sophie Koldkjær Sølling has nothing to declare.


  1. 1.
    Langdahl B, Ferrari S, Dempster DW (2016) Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 8(6):225–235CrossRefGoogle Scholar
  2. 2.
    McClung MR, Langdahl B, Papapoulos S, Saag K, Bone H, Rybak-Feiglin A, Cohn D, DaSilva CA, Massaad7 R, Santora6 AC, Scott6 BB, Kaufman6 KD, Verbruggen7 N, Leung8 A, Lombardi A (2015) Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial (LOFT). ECTS-IBMS Abstr OC4:4Google Scholar
  3. 3.
    Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A (2015) Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 26(2):699–712CrossRefGoogle Scholar
  4. 4.
    Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733–759CrossRefGoogle Scholar
  5. 5.
    Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401–419CrossRefGoogle Scholar
  6. 6.
    Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36(5):315–328CrossRefGoogle Scholar
  7. 7.
    Black DM, Schwartz AV, Ensrud KE, a Cauley J, Levis S, a Quandt S, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938CrossRefGoogle Scholar
  8. 8.
    Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25(5):976–982CrossRefGoogle Scholar
  9. 9.
    Miller PD, Bolognese M a, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222–229CrossRefGoogle Scholar
  10. 10.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang Y-C, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972–980CrossRefGoogle Scholar
  11. 11.
    Brown JP, Roux C, Törring O, Ho P-R, Beck Jensen J-E, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res 28(4):746–752CrossRefGoogle Scholar
  12. 12.
    Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res 33(2):190–198CrossRefGoogle Scholar
  13. 13.
    Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28(10):3067–3068CrossRefGoogle Scholar
  14. 14.
    Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101(4):371–374CrossRefGoogle Scholar
  15. 15.
    Horne AM, Mihov B, Reid IR (2018) Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif Tissue Int 103:55–61CrossRefGoogle Scholar
  16. 16.
    Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Dasilva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27(11):2251–2258CrossRefGoogle Scholar
  17. 17.
    Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26(2):242–251CrossRefGoogle Scholar
  18. 18.
    Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27(5):1923–1925CrossRefGoogle Scholar
  19. 19.
    Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporos Int 27(5):1917–1921CrossRefGoogle Scholar
  20. 20.
    Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291–1296CrossRefGoogle Scholar
  21. 21.
    Binkley N, Krueger D, de Papp AE (2018) Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib. Osteoporos Int 29(4):999–1002CrossRefGoogle Scholar
  22. 22.
    Zhuo Y, Gauthier J-Y, Black WC, Percival MD, Duong LT (2014) Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone 67:269–280CrossRefGoogle Scholar
  23. 23.
    Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30(5):934–944CrossRefGoogle Scholar
  24. 24.
    Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27(2):243–254CrossRefGoogle Scholar
  25. 25.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Pivotal Fracture Trial HORIZON (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRefGoogle Scholar
  26. 26.
    Polyzos SA, Anastasilakis AD, Terpos E (2009) Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer 17(10):1329–1330CrossRefGoogle Scholar
  27. 27.
    Duong LT, Crawford R, Scott K, Winkelmann CT, Wu G, Szczerba P, Gentile MA (2016) Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia. Bone 93:86–96CrossRefGoogle Scholar
  28. 28.
    Polyzos SA, Terpos E (2016) Clinical vertebral fractures following denosumab discontinuation. Endocrine 54(1):271–272CrossRefGoogle Scholar
  29. 29.
    Anastasilakis AD, Makras P Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos IntGoogle Scholar
  30. 30.
    Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2016) Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. In: J. Clin. Endocrinol. Metab., p. jc20163170, pp jc.2016–jc.3170Google Scholar
  31. 31.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2017) Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos IntGoogle Scholar
  32. 32.
    Franck H, Munz M, Scherrer M (1995) Evaluation of dual-energy X-ray absorptiometry bone mineral measurement--comparison of a single-beam and fan-beam design: the effect of osteophytic calcification on spine bone mineral density. Calcif Tissue Int 56(3):192–195CrossRefGoogle Scholar
  33. 33.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  • A.S. Koldkjær Sølling
    • 1
    Email author
  • T. Harsløf
    • 1
  • B. Langdahl
    • 1
  1. 1.Department of Endocrinology and Internal MedicineAarhus University HospitalAarhus NDenmark

Personalised recommendations